Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab

Rothenberg, Marc E.; Klion, Amy D.; Roufosse, Florence E.; Kahn, Jean Emmanuel; Weller, Peter Fahey; Simon, Hans-Uwe; Schwartz, Lawrence B.; Rosenwasser, Lanny J.; Ring, Johannes; Griffin, Elaine F.; Haig, Ann E.; Frewer, Paul I.H.; Parkin, Jacqueline M.; Gleich, Gerald J.

doi:10.1056/nejmoa070812.

Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab

By Marc E. Rothenberg, Amy D. Klion, Florence E. Roufosse, Jean Emmanuel Kahn, Peter Fahey Weller, Hans-Uwe Simon, Lawrence B. Schwartz, Lanny J. Rosenwasser, Johannes Ring, Elaine F. Griffin, Ann E. Haig, Paul I.H. Frewer, Jacqueline M. Parkin and Gerald J. Gleich

Abstract

The hypereosinophilic syndrome is a group of diseases characterized by persistent blood eosinophilia, defined as more than 1500 cells per microliter with end-organ involvement and no recognized secondary cause. Although most patients have a response to corticosteroids, side effects are common and can lead to considerable morbidity

Publisher: 'Massachusetts Medical Society'

Year: 2016

DOI identifier: 10.1056/nejmoa070812.

OAI identifier: oai:dash.harvard.edu:1/28702415

Provided by: Harvard University - DASH

Journal:

Download PDF:
_{Sorry, we are unable to provide the full text but you may find it at the
following location(s):}

http://nrs.harvard.edu/urn-3:H... (external link)

Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab

Abstract

Suggested articles